When patients receiving anticoagulation therapy undergo invasive procedures, management requires an individualized assessment of the risk of bleeding versus the risk of thrombosis. This review explains management, including bridging anticoagulation for patients receiving warfarin.
"The management of those patients requires an involvement of all participating teams (general practitioners, surgeons, anesthesiologists , and other healthcare professionals involved in invasive procedures). Their cessation is indisputable in most elective procedure, but the risk between thrombosis and bleeding should be balanced . In some settings, the therapeutic window is bridged by low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to prevent thromboembolic risk  . "
[Show abstract][Hide abstract] ABSTRACT: The field of oral anticoagulation has evolved with the arrival of non-vitamin K antagonist oral anticoagulants (NOACs) including
an anti-IIa agent (dabigatran etexilate) and anti-Xa agents (rivaroxaban and apixaban). The main specificities of these drugs
are predictable pharmacokinetics and pharmacodynamics but special attention should be paid in the elderly, in case of renal
dysfunction and in case of emergency. In addition, their perioperative management is challenging, especially with the absence
of specific antidotes. Effectively, periods of interruption before surgery or invasive procedures depend on half-life and keeping
a permanent balance between bleeding and thromboembolic risks. In addition, few data regarding the link between plasma
concentrations and their effects are provided. Routine laboratory tests are altered by NOACs and quantitative measurements are
not widely performed. This paper provides a review on the management of NOACs in the perioperative setting, including the
estimation of the bleeding and thrombotic risk, the periods of interruption, the indication of heparin bridging, the usefulness of
laboratory tests before surgery or invasive procedure, and the time of resuming. Most data are based on expert’s opinions.
BioMed Research International 09/2014; 2014(385014):16. DOI:10.1155/2014/385014 · 2.71 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Periprocedural management of antithrombotics for gastroenterological endoscopy is a common clinical issue. To decide how to manage the use of antithrombotics in patients undergoing endoscopy, the risk for hemorrhage and thromboembolism during the procedure must be considered. For low-risk procedures, no adjustments in antithrombotics are needed. For high-risk procedures with a low thromboembolic risk, discontinuation of warfarin at 5 days, and clopidogrel at 5 to 7 days before the procedure has been recommended. However, it is better to continue aspirin use even during high-risk procedures. A heparin bridging therapy may be considered before endoscopy in patients with a high thromboembolic risk. The management of patients taking antithrombotics remains complex, especially in high-risk settings.
[Show abstract][Hide abstract] ABSTRACT: Dabigatran etexilate (DE), rivaroxaban, and apixaban are nonvitamin K antagonist oral anticoagulants (NOACs) that have been
compared in clinical trials with existing anticoagulants (warfarin and enoxaparin) in several indications for the prevention and
treatment of thrombotic events. All NOACs presented bleeding events despite a careful selection and control of patients. Compared
with warfarin, NOACs had a decreased risk of intracranial hemorrhage, and apixaban and DE (110 mg BID) had a decreased risk
of major bleeding from any site. Rivaroxaban and DE showed an increased risk of major gastrointestinal bleeding compared with
warfarin. Developing strategies to minimize the risk of bleeding is essential, as major bleedings are reported in clinical practice
and specific antidotes are currently not available. In this paper, the following preventive approaches are reviewed: improvement of
appropriate prescription, identification of modifiable bleeding risk factors, tailoring NOAC’s dose, dealing with a missed dose as
well as adhesion to switching, bridging and anesthetic procedures.
BioMed Research International 06/2014; 2014(Article ID 616405). DOI:10.1155/2014/616405 · 3.17 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.